GlassScriptPhysician profile
Christopher David Blanchet
NPI 1124370325
$4,824.66
in general payments reported to CMS, 2019-2025
32 companies · $1,495 in 2025
The $1,495 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $954 · 2022: $842 · 2023: $569 · 2024: $964 · 2025: $1,495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,028.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,129.36 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $689.78 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $473.93 | 2022-2025 | Caplyta |
| Grifols USA, LLC | $299.43 | 2021-2025 | Prolastin-C Liquid |
| Xeris Pharmaceuticals, INC. | $241.03 | 2023-2025 | Gvoke Hypopen |
| Amgen INC. | $230.07 | 2021-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $214.92 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $197.69 | 2021-2025 | |
| Exact Sciences Corporation | $142.69 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $136.71 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $123.94 | 2021-2023 | Rexulti |
| Glaxosmithkline, LLC. | $115.78 | 2021-2025 | Trelegy Ellipta |
| Axsome Therapeutics, INC. | $98.41 | 2023-2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $75.93 | 2023 | |
| Vanda Pharmaceuticals INC. | $74.82 | 2025 | Fanapt |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $72.73 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $67.00 | 2021-2022 | |
| Antares Pharma, INC. | $44.61 | 2024-2025 | Xyosted |
| Merck Sharp & Dohme LLC | $43.68 | 2021 | |
| Corcept Therapeutics | $42.40 | 2025 | Korlym |
| Dexcom, INC. | $39.12 | 2021-2024 | Dexcom G6 Transmitter |
| Scpharmaceuticals INC. | $35.91 | 2025 | |
| Novartis Pharmaceuticals Corporation | $33.98 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $30.79 | 2021 | |
| Esperion Therapeutics, INC. | $29.72 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.36 | 2024 | Glassia |
| Lundbeck LLC | $23.69 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.52 | 2022 | |
| Mylan Specialty L.P. | $19.24 | 2023 | Yupelri |
| Allergan, INC. | $19.17 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $17.64 | 2025 | Zoryve |
| Daiichi Sankyo INC. | $14.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Blanchet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.